Get the Stockscreener App
1.08
9.90%
0.0973
Lucid Diagnostics Inc stock is traded at $1.08, with a volume of 6.00M.
It is up +9.90% in the last 24 hours and up +13.08% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9827
Open:
$1
24h Volume:
6.00M
Relative Volume:
6.41
Market Cap:
$206.03M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-1.3116
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
+10.42%
1M Performance:
+13.08%
6M Performance:
-4.42%
1Y Performance:
-14.29%
1-Day Range:
$0.997
$1.08
1-Week Range:
$0.9574
$1.08
52-Week Range:
$0.90
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.08 | 206.03M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lucid Diagnostics Inc (LUCD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lucid Diagnostics Inc (LUCD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lucid Diagnostics Inc (LUCD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026. - marketscreener.com
Lucid Diagnostics misses on revenue, but 2026 growth outlook lights up bull case - MSN
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case - Benzinga
LUCD Maintained by Ascendiant Capital -- Price Target Raised to $9.25 - GuruFocus
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results - Yahoo Finance
Lucid Diagnostics Q1 2026 Earnings: EPS Miss Widens as Company Reports Wider-Than-Expected LossProfit Inflection Point - newsline.com
LUCD Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue Stage ChallengesRevenue Warning Signal - The Legal Advocate
LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill
LUCD - Finviz
Lucid Diagnostics (LUCD) Surges 7% as Momentum Builds Near Key ResistanceTurnaround Stocks - The Legal Advocate
Lucid Diagnostics Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Firm Advances Commercial Rollout - The Legal Advocate
Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market - Stock Titan
Lucid Diagnostics (LUCD) Rallies +1.30% as Bulls Target $1.02 2026-05-19Dividend Growth Stocks - The Legal Advocate
Lucid Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-05-17 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Upcoming Events - FinancialContent
Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
BTIG Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5 - Moomoo
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q1 2026 Earnings Conference - 富途牛牛
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains By Investing.com - Investing.com Australia
Q1 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript - Insider Monkey
PAVmed (NASDAQ: PAVM) Q1 2026 results, losses and cash position - Stock Titan
PAVmed Q1: cancer test and implantable monitor push toward coverage, FDA - Stock Titan
Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail
Lucid says $44.8M pro forma cash extends runway well into 2027 as it awaits Medicare LCD - MSN
Lucid Diagnostics Inc.Common Stock (NQ: LUCD - FinancialContent
PAVmed Inc.Series Z Warrant (NQ: PAVMZ - FinancialContent
Lucid Diagnostics Earnings Call Balances Progress, Pressure - TipRanks
PAVmed Reports Business Expansion and Financial Update - Intellectia AI
PAVmed (NASDAQ: PAVM) posts Q1 2026 loss and flags going concern risks - Stock Titan
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Releases Q1 2026 Financial Results - AlphaStreet
LUCD Q1 2026 Earnings Transcript - The Globe and Mail
Lucid Diagnostics Q1 Earnings Call Highlights - Yahoo Finance
LUCD: Q1 revenue reached $1.3M on 3,177 tests, with cash runway extended and Medicare approval pending - TradingView
Lucid Diagnostics Reports Q1 2026 Financial Results: $1.3M Revenue, Strong Cash Position, and Medicare Reimbursement Milestone Progress - Minichart
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
Aug 20 '25 |
Buy |
1.02 |
100,000 |
101,840 |
665,443 |
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):